News | October 09, 2025
Briefs: Panacea Biotec and Shukra Pharmaceuticals
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Panacea Biotec receives acceptance from CMSS for supply of bOPV
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
New study presents a human-relevant stress model for assessing potential therapeutics
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
